{"id":"consolidation-carboplatin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Carboplatin is a platinum-based chemotherapy drug that binds to DNA, causing cross-links and inhibiting DNA replication. This leads to cell death, particularly in rapidly dividing cancer cells. The exact mechanism is not fully understood, but it is thought to involve the formation of platinum-DNA adducts that trigger apoptosis.","oneSentence":"Carboplatin works by interfering with DNA replication in cancer cells, leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:28:17.620Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Non-small cell lung cancer"},{"name":"Breast cancer"},{"name":"Testicular cancer"}]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06667908","phase":"PHASE2","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2024-12-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT06193759","phase":"PHASE1","title":"Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-09-20","conditions":"Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes","enrollment":12},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT04892953","phase":"PHASE2","title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-07-07","conditions":"Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8","enrollment":51},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT07082179","phase":"PHASE2","title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-09-04","conditions":"NSCLC","enrollment":33},{"nctId":"NCT03141359","phase":"PHASE2","title":"Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2017-05-12","conditions":"Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT02525757","phase":"PHASE2","title":"MPDL3280A With Chemoradiation for Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-01-26","conditions":"Lung Cancer, Non-Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07306663","phase":"PHASE3","title":"Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2021-06-01","conditions":"Esophageal Cancer","enrollment":242},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT07291102","phase":"PHASE3","title":"Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2026-07-01","conditions":"Medulloblastoma","enrollment":96},{"nctId":"NCT04765709","phase":"PHASE2","title":"Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-09-24","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":10},{"nctId":"NCT03916419","phase":"PHASE2","title":"Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-06-20","conditions":"Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":26},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT02605421","phase":"PHASE2","title":"Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-06","conditions":"Neuroblastoma","enrollment":12},{"nctId":"NCT02186847","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2014-08","conditions":"Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma","enrollment":170},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT06448910","phase":"PHASE2","title":"Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC, Locally Advanced Lung Carcinoma","enrollment":41},{"nctId":"NCT04665765","phase":"PHASE2","title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-01-18","conditions":"Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","enrollment":41},{"nctId":"NCT05796089","phase":"PHASE2","title":"Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2022-01-01","conditions":"Extensive-Stage Small-Cell Lung Cancer","enrollment":35},{"nctId":"NCT06420908","phase":"NA","title":"Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"WITHDRAWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-05-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT04046575","phase":"PHASE1","title":"Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-11-07","conditions":"Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus","enrollment":12},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT01652820","phase":"PHASE2","title":"Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2001-10","conditions":"Non Small-cell Lung Cancer","enrollment":140},{"nctId":"NCT04478292","phase":"PHASE3","title":"A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2021-03-01","conditions":"Hepatoblastoma","enrollment":330},{"nctId":"NCT04585490","phase":"PHASE3","title":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","status":"RECRUITING","sponsor":"Maximilian Diehn","startDate":"2021-08-25","conditions":"Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc","enrollment":48},{"nctId":"NCT06522360","phase":"PHASE2","title":"Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-12-11","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03574649","phase":"PHASE2","title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT04943445","phase":"PHASE2","title":"Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latin American Cooperative Oncology Group","startDate":"2022-02-22","conditions":"Squamous Cell Carcinoma of Larynx","enrollment":43},{"nctId":"NCT00554788","phase":"PHASE3","title":"Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-05-06","conditions":"Extraocular Retinoblastoma","enrollment":60},{"nctId":"NCT04364048","phase":"PHASE2","title":"Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Rachel Sanborn","startDate":"2020-06-18","conditions":"Lung Cancer, Non-small Cell Carcinoma","enrollment":10},{"nctId":"NCT01993810","phase":"PHASE3","title":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2014-02-03","conditions":"Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","enrollment":330},{"nctId":"NCT06597513","phase":"PHASE1, PHASE2","title":"Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Zhou Chengzhi","startDate":"2024-12","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT06613308","phase":"","title":"Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Capital Medical University","startDate":"2024-09-25","conditions":"Lung Cancer (NSCLC)","enrollment":20},{"nctId":"NCT02492867","phase":"NA","title":"A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2016-01-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":49},{"nctId":"NCT06438614","phase":"PHASE2","title":"A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2020-08-20","conditions":"Refractory Neuroblastoma, Soft Tissue Cancer","enrollment":47},{"nctId":"NCT04838652","phase":"PHASE2","title":"Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2024-03-05","conditions":"Classical Hodgkin Lymphoma","enrollment":29},{"nctId":"NCT06295926","phase":"PHASE2","title":"Serplulimab Combined With CCRT for LS-SCLC.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-04","conditions":"Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT04158440","phase":"PHASE3","title":"Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2020-04-07","conditions":"Stage II-III Non-small Cell Lung Cancer","enrollment":501},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT05443646","phase":"PHASE2","title":"Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-09-23","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":55},{"nctId":"NCT00653068","phase":"PHASE3","title":"Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-10","conditions":"Childhood Atypical Teratoid/Rhabdoid Tumor","enrollment":70},{"nctId":"NCT00110110","phase":"PHASE2","title":"Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2004-06","conditions":"Retinoblastoma","enrollment":71},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT01526603","phase":"NA","title":"High Dose Chemotherapy and Autologous Transplant for Neuroblastoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-03-28","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT02567799","phase":"PHASE1, PHASE2","title":"BIO 300 Non-Small Cell Lung Cancer Study","status":"COMPLETED","sponsor":"Humanetics Corporation","startDate":"2015-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":21},{"nctId":"NCT02073968","phase":"PHASE2","title":"PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2013-07","conditions":"Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT04992780","phase":"PHASE2","title":"Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-25","conditions":"Non Small Cell Lung Cancer Stage","enrollment":50},{"nctId":"NCT00828009","phase":"PHASE2","title":"BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-01-17","conditions":"Lung Cancer","enrollment":70},{"nctId":"NCT05872724","phase":"PHASE2","title":"Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","status":"RECRUITING","sponsor":"Suzhou Municipal Hospital","startDate":"2023-01-16","conditions":"Cervical Cancer","enrollment":32},{"nctId":"NCT03102242","phase":"PHASE2","title":"Atezolizumab Immunotherapy in Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-11-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":64},{"nctId":"NCT01912625","phase":"PHASE1","title":"Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-28","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":16},{"nctId":"NCT03064867","phase":"PHASE1, PHASE2","title":"Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Molly Gallogly","startDate":"2017-06-26","conditions":"Diffuse Large B-cell-lymphoma","enrollment":65},{"nctId":"NCT05484583","phase":"PHASE2","title":"Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2022-08-01","conditions":"Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy","enrollment":58},{"nctId":"NCT00533949","phase":"PHASE3","title":"High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2007-11","conditions":"Lung Cancer, Radiation Toxicity","enrollment":544},{"nctId":"NCT00712582","phase":"PHASE2","title":"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT00979212","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-02","conditions":"Lung Cancer","enrollment":71},{"nctId":"NCT05394415","phase":"PHASE1, PHASE2","title":"Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-05-01","conditions":"Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation","enrollment":30},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT01757288","phase":"PHASE1, PHASE2","title":"Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-03-25","conditions":"STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER","enrollment":98},{"nctId":"NCT05050630","phase":"PHASE2","title":"Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2021-08-01","conditions":"Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed","enrollment":73},{"nctId":"NCT04982549","phase":"PHASE2","title":"A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2021-01-21","conditions":"Unresectable Stage III NSCLC","enrollment":35},{"nctId":"NCT04084158","phase":"PHASE2","title":"A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.","status":"SUSPENDED","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-09-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT03699033","phase":"PHASE2","title":"Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Stephanie Smiddy","startDate":"2018-10-01","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03945227","phase":"PHASE2","title":"Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2019-06","conditions":"Stage III NSCLC","enrollment":""},{"nctId":"NCT02412371","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-04-30","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":48},{"nctId":"NCT04453904","phase":"NA","title":"Modality of Adjuvant Radiotherapy and Chemotherapy for Stage Ⅲ Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2020-05-12","conditions":"Endometrial Cancer","enrollment":654},{"nctId":"NCT04203511","phase":"PHASE3","title":"INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2020-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02792036","phase":"PHASE1","title":"Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-01","conditions":"Retinoblastoma","enrollment":8},{"nctId":"NCT04261465","phase":"PHASE2","title":"NUVOLA TRIAL Open-label Multicentre Study","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-12-01","conditions":"High Grade Serous Ovarian Cancer","enrollment":35},{"nctId":"NCT00096226","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2004-09","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT01196429","phase":"PHASE2","title":"Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08","conditions":"Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":90},{"nctId":"NCT01822496","phase":"PHASE2","title":"Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-04","conditions":"Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7","enrollment":59},{"nctId":"NCT00547443","phase":"PHASE1, PHASE2","title":"Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Lung Cancer","enrollment":""},{"nctId":"NCT00520013","phase":"PHASE2","title":"Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":60},{"nctId":"NCT00738452","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-08-06","conditions":"Lung Cancer","enrollment":10},{"nctId":"NCT01486602","phase":"PHASE1","title":"Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-03","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT00258362","phase":"PHASE2","title":"Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-07","conditions":"Endometrial Cancer","enrollment":41},{"nctId":"NCT02172846","phase":"PHASE1","title":"Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-05-22","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":23},{"nctId":"NCT00094861","phase":"PHASE2","title":"Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer","enrollment":100},{"nctId":"NCT00492206","phase":"PHASE2","title":"Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-06","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":40},{"nctId":"NCT00449020","phase":"PHASE2","title":"Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-01","conditions":"Lung Cancer","enrollment":32},{"nctId":"NCT02787473","phase":"PHASE2","title":"A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2016-10","conditions":"Squamous Cell Lung Cancer","enrollment":54},{"nctId":"NCT00117962","phase":"PHASE2","title":"Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-09","conditions":"Lung Cancer","enrollment":109},{"nctId":"NCT00039195","phase":"PHASE2","title":"Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11","conditions":"Lymphoma","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Consolidation Carboplatin","genericName":"Consolidation Carboplatin","companyName":"Radiation Therapy Oncology Group","companyId":"radiation-therapy-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin works by interfering with DNA replication in cancer cells, leading to cell death. Used for Ovarian cancer, Non-small cell lung cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}